Chairs: Dhanpat Jain (USA) – Rupert Langer (Austria)

1. Are the histologic features of ICI induced esophagitis specific? Celia Marginean (USA)
2. What are the challenges with PDL1 scoring (CPS/TAP) for esophageal carcinoma? Cathy Streutker (Canada)
3. What are the challenges of margins evaluation for dysplasia carcinoma in ESD for esophageal neoplasia: Does it even matter? Mikhail Lisovsky (USA)
4. Is there a need to count Eosinophils in biopsies during follow-up of EOE biopsies during follow-up of EOE? Suntrea Hammer (USA)
5. Is there any role in sub-typing BE dysplasia: Intestinal vs. foveolar? Monika Tripathi (Canada)
6. What is the significance of epidermoid metaplasia in the esophagus? Xuchen Zhang (USA)
7. What are the challenges of evaluation and reporting of p53 in BE for dysplasia? Ilke Nalbantoglu (USA)
8. What are the advantages and disadvantages of various systems for evaluating post-therapy tumor regression? Florence Renaud (France)
9. Current role of digital pathology and AI in esophageal carcinoma and treatment response? Bastian Dislich (Switzerland)
10. Updates on WHO classification 6th edition and staging of esophageal carcinoma? Deyali Chatterjee (USA)
11. What are current and upcoming biomarkers for esophageal carcinomas? Lei Zhao (USA)